We treated these 3 LNCaP cell types with two antiandrogens, i.e., bicalutamide and MDV3100 (MDV; Enzalutamide), two chemotherapeutic drugs (etoposide and docetaxel), and two molecularly targeted drugs, i.e., ABT-199, which selectively inhibits Bcl-2 [26, 27], and AEW541, an inhibitor of IGF-1R [28], which is important for the PSA−/lo PCa cells [13]. Here, BCL2 is linked to posterior cortical atrophy.